{"id":9920,"date":"2025-05-26T20:32:21","date_gmt":"2025-05-26T20:32:21","guid":{"rendered":"https:\/?page_id=9920"},"modified":"2025-06-06T16:54:25","modified_gmt":"2025-06-06T16:54:25","slug":"neuroimmunology-2","status":"publish","type":"page","link":"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/","title":{"rendered":"Neuroimmunology"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tNeuroimmunology\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h1>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Neuroimmunology explores how the immune system interacts with the central and peripheral nervous systems, offering insight into disorders ranging from multiple sclerosis to autoimmune encephalitis and neurodegeneration. Innovations in this space are enabling the development of targeted therapies to modulate immune responses, protect neurons, and slow disease progression. Pharma and biotech leaders are translating immunological breakthroughs into novel treatments for both inflammatory and degenerative neurologic diseases.<\/p>

\u00a0<\/p>

Key Focus Areas<\/b>:<\/h5>

\u00a0<\/p>

  • B-Cell Depletion Therapies<\/strong>
    Monoclonal antibodies targeting CD20 (e.g., ocrelizumab, ofatumumab) to reduce autoreactive B cells in MS and neuroautoimmune disorders.<\/p><\/li>

  • T-Cell Modulation & Trafficking Inhibition<\/strong>
    S1P receptor modulators and adhesion molecule blockers to limit lymphocyte entry into the CNS.<\/p><\/li>

  • Complement Inhibition in Neuroinflammation<\/strong>
    C5 and C1 inhibitors to reduce CNS damage in neuromyelitis optica spectrum disorder (NMOSD), myasthenia gravis, and neurodegeneration.<\/p><\/li>

  • Anti-IL-6 and Cytokine-Targeted Therapies<\/strong>
    Targeting IL-6, GM-CSF, and other cytokines implicated in neuroinflammatory and demyelinating conditions.<\/p><\/li>

  • Checkpoint Modulation in CNS Autoimmunity<\/strong>
    Exploring PD-1\/PD-L1 and CTLA-4 pathways in diseases like MS to rebalance immune responses.<\/p><\/li>

  • FcRn Blockade<\/strong>
    Inhibiting neonatal Fc receptors to reduce pathogenic IgG levels in diseases like myasthenia gravis and autoimmune encephalitis.<\/p><\/li>

  • Neuroprotective Immunomodulation<\/strong>
    Therapies aiming to reduce inflammation while preserving neuronal integrity and promoting remyelination.<\/p><\/li>

  • CNS-Penetrant JAK\/BTK Inhibitors<\/strong>
    Small molecules capable of modulating intracellular immune signaling across the blood-brain barrier.<\/p><\/li>

  • Cell Therapy in Neuroimmune Disease<\/strong>
    Investigational use of Tregs, MSCs, and tolerogenic dendritic cells for immune reprogramming in neurologic conditions.<\/p><\/li>

  • Biomarker-Guided Therapy & CNS Immune Monitoring<\/strong>
    Use of neurofilament light chain (NfL), cytokine panels, and CSF immune markers to track disease activity and treatment response.<\/p><\/li>

  • Others<\/p><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Neuroimmunology explores how the immune system interacts with the central and peripheral nervous systems, offering insight into disorders ranging from multiple sclerosis to autoimmune encephalitis and neurodegeneration. Innovations in this space are enabling the development of targeted therapies to modulate immune responses, protect neurons, and slow disease progression. Pharma and biotech leaders are translating immunological […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9920","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nNeuroimmunology - Alliance for Immunology Innovations (AII)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuroimmunology - Alliance for Immunology Innovations (AII)\" \/>\n<meta property=\"og:description\" content=\"Neuroimmunology explores how the immune system interacts with the central and peripheral nervous systems, offering insight into disorders ranging from multiple sclerosis to autoimmune encephalitis and neurodegeneration. Innovations in this space are enabling the development of targeted therapies to modulate immune responses, protect neurons, and slow disease progression. Pharma and biotech leaders are translating immunological […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Alliance for Immunology Innovations (AII)\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-06T16:54:25+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/neuroimmunology-2\\\/\",\"url\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/neuroimmunology-2\\\/\",\"name\":\"Neuroimmunology - Alliance for Immunology Innovations (AII)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/#website\"},\"datePublished\":\"2025-05-26T20:32:21+00:00\",\"dateModified\":\"2025-06-06T16:54:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/neuroimmunology-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/neuroimmunology-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/neuroimmunology-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuroimmunology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/#website\",\"url\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/\",\"name\":\"Alliance for Immunology Innovations (AII)\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuroimmunology - Alliance for Immunology Innovations (AII)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/","og_locale":"en_US","og_type":"article","og_title":"Neuroimmunology - Alliance for Immunology Innovations (AII)","og_description":"Neuroimmunology explores how the immune system interacts with the central and peripheral nervous systems, offering insight into disorders ranging from multiple sclerosis to autoimmune encephalitis and neurodegeneration. Innovations in this space are enabling the development of targeted therapies to modulate immune responses, protect neurons, and slow disease progression. Pharma and biotech leaders are translating immunological […]","og_url":"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/","og_site_name":"Alliance for Immunology Innovations (AII)","article_modified_time":"2025-06-06T16:54:25+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/","url":"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/","name":"Neuroimmunology - Alliance for Immunology Innovations (AII)","isPartOf":{"@id":"https:\/\/eutranslationalmedicine.org\/aii\/#website"},"datePublished":"2025-05-26T20:32:21+00:00","dateModified":"2025-06-06T16:54:25+00:00","breadcrumb":{"@id":"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eutranslationalmedicine.org\/aii\/neuroimmunology-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eutranslationalmedicine.org\/aii\/"},{"@type":"ListItem","position":2,"name":"Neuroimmunology"}]},{"@type":"WebSite","@id":"https:\/\/eutranslationalmedicine.org\/aii\/#website","url":"https:\/\/eutranslationalmedicine.org\/aii\/","name":"Alliance for Immunology Innovations (AII)","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eutranslationalmedicine.org\/aii\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/comments?post=9920"}],"version-history":[{"count":8,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9920\/revisions"}],"predecessor-version":[{"id":10043,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9920\/revisions\/10043"}],"wp:attachment":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/media?parent=9920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}